Compare Amphastar Pharmaceuticals Inc (AMPH) vs Upwork Inc (UPWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Upwork Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Upwork Inc trades at $8.89 (market cap $1.09B). The key difference: Upwork Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| AMPH | UPWK | |
|---|---|---|
Market Cap | $826.08M | $1.09B |
Sector | Health | Industrials |
52-Week High | $30.81 | $22.11 |
52-Week Low | $16.87 | $7.84 |
Enterprise Value | $1.22B | $890.41M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
UPWK trades at $8.82, up 1.61% today, but faces a bearish technical signal with recent earnings misses in Q3 2025, Q4 2025, and Q1 2026. The company reported 2025 revenue of $787.78M with a net income margin of 13.81%, while valuation metrics like a P/E of 10.9 and P/S of 1.55 appear reasonable. However, multiple law firms are investigating potential securities fraud, contributing to negative sentiment after a 19% stock drop post-Q1 2026 results.
The outlook is mixed: analyst consensus is a Buy with a $10.67 price target, but risks include ongoing legal probes, earnings volatility, and competitive pressures in the gig economy. Upside depends on execution improvements and AI integration initiatives like the Upwork Claude Connector announced in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
